PERCH

PERCH - PartnERship to Contrast HPV

HPV can cause cervical cancer in women and anogenital and head and neck cancers in both sexes. HPV 16 and HPV 18 genotypes cause around 70% of cases of cervical cancer, which kills around 26 000 women a year in Europe.

Cervical cancer is highly preventable through HPV vaccination and screening. However, in 2020 vaccination programme coverage in the WHO European region was only 31%.

PERCH supports national HPV vaccination efforts by improving:

EU Member State capacities to plan and implement vaccination campaigns;
HPV vaccination and cervical cancer screening data and monitoring systems;
awareness of HPV-related disease and its prevention among adolescents;
healthcare professionals’ abilities to communicate the need for vaccination.

Project duration: 1 Nov 2022 - 30 Apr 2025
Project locations: Belgium
Croatia
Czechia
Estonia
France
Germany
Greece
Hungary
Ireland
Italy
Norway
Lithuania
Poland
Romania
Slovenia
Slovakia
Spain
Sweden

Overall budget: €4 750 000
EU contribution: €3 800 000
80% of the overall budget

Project website: Project PERCH Site

EU4health - Projects

Prevention

8 AUGUST 2023

FS CANCER_PERCH

4 JUNE 2024

EU Funding & Tenders Portal - PERCH

Results

Short-term outcomes

Increased awareness of how HPV vaccination and cervical cancer screening are implemented and monitored in Member States.
Increased awareness of the benefits of HPV vaccination among target groups.
Stronger national and international stakeholder networks.
Empowerment of countries to obtain HPV vaccines at the lowest possible price.

Medium/long-term outcomes

Increased HPV vaccine coverage in all or most European countries.
European cervical cancer incidence of less than four per 100 000 per year.
Reduced incidence of all HPV-related cancers and associated mortality in Europe.